CC
VRDN icon

Commodore Capital’s Viridian Therapeutics VRDN Stock Holding History

Commodore Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,200,000
Closed -$69.1M – 41
2025
Q3 		$69.1M Sell
3,200,000
-1,675,000
-34% -$30.2M 3.37% 12
2025
Q2 		$68.2M Buy
4,875,000
+1,275,000
+35% +$17.3M 4.81% 8
2025
Q1 		$48.5M Buy
3,600,000
+1,200,000
+50% +$20.4M 3.58% 13
2024
Q4 		$46M Sell
2,400,000
-150,124
-6% -$3.26M 3.37% 12
2024
Q3 		$58M Buy
2,550,124
+22,092
+0.9% +$361K 3.63% 11
2024
Q2 		$32.9M Buy
2,528,032
+593,379
+31% +$8.21M 2.25% 17
2024
Q1 		$33.9M Buy
1,934,653
+10,579
+0.5% +$205K 2.27% 16
2023
Q4 		$41.9M Sell
1,924,074
-275,926
-13% -$4.36M 3.66% 9
2023
Q3 		$33.7M Hold
2,200,000
– – 3.94% 12
2023
Q2 		$52.3M Buy
2,200,000
+10,341
+0.5% +$265K 5.88% 6
2023
Q1 		$55.7M Buy
2,189,659
+169,493
+8% +$5.43M 8.48% 2
2022
Q4 		$59M Sell
2,020,166
-676,174
-25% -$15.6M 8.89% 2
2022
Q3 		$55.3M Buy
2,696,340
+1,057,731
+65% +$19M 8.89% 3
2022
Q2 		$19M Buy
1,638,609
+687,270
+72% +$9.24M 4.01% 10
2022
Q1 		$17.6M Buy
951,339
+103,656
+12% +$1.99M 3.93% 10
2021
Q4 		$16.8M Buy
847,683
+180,009
+27% +$3.35M 3.88% 10
2021
Q3 		$11M Buy
667,674
+481,269
+258% +$7.06M 2.9% 14
2021
Q2 		$3.41M Buy
186,405
+624
+0.3% +$10.7K 1.19% 27
2021
Q1 		$3.1M Buy
+185,781
New +$3.48M 1.24% 27

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Commodore Capital's VRDN Position: Q4 2025 in Review

Commodore Capital sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 3,200,000 shares — an estimated $69.1M sold.

Commodore Capital first reported a position in VRDN in Q1 2021 and held it in 19 quarters. The position peaked at $69.1M in Q3 2025. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Commodore Capital reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Commodore Capital sold 3,200,000 Viridian Therapeutics shares in Q4 2025, an estimated $69.1M.
  • Commodore Capital first reported a position in Viridian Therapeutics in Q1 2021 and held it in 19 quarters.
  • Commodore Capital's Viridian Therapeutics position peaked at $69.1M in Q3 2025.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Commodore Capital's 13F filing for Q4 2025, filed 17 Feb 2026.